The DISCOVER study is a clinical trial of PrEP to test whether a combination of emtricitabine and tenofovir alafenamide (F/TAF) is as safe and effective as Truvada® (emtricitabine and tenofovir disoproxil fumarate, F/TDF) at reducing the risk of HIV infection when used as PrEP. F/TAF was recently approved for HIV treatment, but it is not yet known whether it is effective as PrEP.
This is a double blind randomised controlled trial where participants in the study are randomly allocated to get either active Truvada® and placebo F/TAF or active F/TAF and placebo Truvada®. Neither the participants nor the study clinicians will known which drug the participant is taking until the end of the study. Participants are followed up 3 monthly for 2 years and are told which drug they were getting at the end of study follow up.
The DISCOVER is a new clinical study for is recruiting men who have sex with men and trans women who have sex with men. This study is to evaluate if a once-daily investigational medicine can help reduce the risk of getting HIV infection from sex (“PrEP”, or Pre-exposure Prophylaxis). TO BE ELIGIBLE:
- You must be at least 18 years of age
- You must be HIV negative
- at risk of acquiring HIV
If you are accepted into the DISCOVER Study, you will receive study-related exams, lab tests, and study medicine at no cost.
For more information, please contact the Gay Men’s Clinic or
the ROAM team directly:
Gay Men’s Clinic
2a Chalmers St
0131 536 1070 for appointments and advice.
2a Chalmers St
0131 5361773 or 07774628227
Or go to https://clinicaltrials.gov/ct2/show/NCT02842086?term=02842086